THE-630

News alerts, weekly reports and conference planners

Company:

Concentra Biosciences

Drug class:

pan-KIT inhibitor

‹

›

almost2years

A Study of THE-630 in Patients With Advanced Gastrointestinal Stromal Tumors (GIST) (clinicaltrials.gov)

P1/2, N=32, Terminated, Theseus Pharmaceuticals | Active, not recruiting --> Terminated; The Sponsor terminated the study due to early dose-limiting toxicities.

almost 2 years ago

Trial termination • Stroma • Metastases

sunitinib • THE-630

almost3years

Initial results from the phase (ph) 1 portion of a ph 1/2 study of THE-630 in patients (pts) with advanced gastrointestinal stromal tumor (GIST). (ASCO 2023)

First-line imatinib provides initial clinical benefit in advanced disease, but prognosis is poor for pts whose tumors progress, despite 3 other approved tyrosine kinase inhibitors (TKIs). THE-630 had an acceptable initial safety profile, and escalation continues, as target exposure for pan-variant KIT activity is not yet reached. Reduction in KIT-mutant allele fractions in ctDNA and initial evidence of disease control were observed. Clinical trial information: NCT05160168.

almost 3 years ago

Clinical • Stroma • Metastases

KIT mutation

Guardant360® CDx

imatinib • THE-630